Abstract Library

#4315 The indolent nature of type 1 gastric neuroendocrine tumours under 1cm: Insights from a dual-centre study

Introduction: Current guidelines primarily recommend endoscopic surveillance for type 1 gastric neuroendocrine tumours (g-NETs) measuring ≤10mm, though these guidelines are largely based on expert consensus rather than strong evidence.

Conference:

Presenting Author:

Authors: Dell' Unto E, Riding G, Rimondi A, Rinzivillo M, Esposito G,

Keywords: Gastric Neuroendocrine Tumour, Carcinoid, Endoscopic Surveillance,

#4288 A virtual patient handbook

Introduction: Neuroendocrine cancer has lower public recognition than more common cancer types and when this is combined with geographical inequalities in neuroendocrine cancer care across the UK, patients can often find themselves reliant on online resources to educate themselves about the disease.

Conference:

Presenting Author:

Authors: Chesser B,

Keywords: patient handbook, digital resources, patient information, multi-media,

#3882 Adjuvant therapy for pancreatic neuroendocrine tumors – Expert consensus and recommendations for future research

Introduction: With the increase of incidentally diagnosed pancreatic neuroendocrine tumors (panNEN), more patients are treated with curative intent. Survival in patients with a panNEN is impacted by the development of recurrence, but postoperative adjuvant therapy is not yet recommended in guidelines due to absence of evidence. Multiple clinicopathological characteristics have been described in literature to identify patients at high-risk of recurrence who might benefit from adjuvant treatment. Since panNEN are rare tumors, prospective randomized controlled studies on the role of adjuvant therapy in these patients have not been performed.

Conference:

Presenting Author: Heidsma C

Authors: Heidsma C, Engelsman A, Klümpen H, Falconi M, Frilling A,

Keywords: pancreatic neuroendocrine tumor, recurrence, adjuvant therapy, prevention, expert consensus, future research,

#3692 Improvement of lung NET management through standardized care – A Swiss nationwide observational study

Introduction: Typical (TC) and atypical carcinoids (AC) are the most common neuroendocrine tumors (NETs) of the lung. Being a rare disease, the management of these tumors varies widely among Swiss centers. The impact of guidelines introduced in 2015 is unknown.

Conference:

Presenting Author: Schmidlin M

Authors: Schmidlin M, Sadowski S, Siebenhüner A, Wild D, Christ E,

Keywords: pulmonary carcinoid, survival analysis, registry,

#2189 Perioperative Chemotherapy in Resectable Neuroendocrine Carcinomas of the Digestive Tract

Introduction: Neuroendocrine carcinomas (NEC), of the digestive tract are rare and aggressive tumours. In localised disease, the treatment is surgery, followed by administration of adjuvant chemotherapy combining etoposide and platinum salts, justified by the high risk of secondary metastasis. No clinical study has proven the benefit of chemotherapy, and recommendations are based on expert consensus.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pellat A, Walter T, Hautefeuille V, Hentic O, Augustin J,

Keywords: neuroendocrine, carcinoma, chemotherapy, Ki-67,